InvestSMART

Mesoblast Limited (ASX:MSB)

ALERT: Price-sensitive ASX Announcement for MSB
Current share price for MSB : $2.380 0.28 (13.33%)+
Announcement
Release
10 Jul 2026 9:57AM
Price at Release
$2.100
Full Release
download
Summary
Mesoblast Limited announced that their product, Ryoncil® (remestemcel-L-rknd), achieved a net revenue of US$36 million for the fourth quarter and US$115 million for the full financial year ending June 30, 2026. The product is FDA-approved for treating steroid-refractory acute graft-versus-host disease in children under age 12. Mesoblast's CEO, Dr. Silviu Itescu, highlighted that the revenue exceeded initial projections and expressed optimism for continued growth in the following fiscal year, supported by a robust capital position and strategic initiatives aimed at expanding product indications.
Key Points
  • RYONCIL delivers net revenue of US$36M for Q4 ending June 30, 2026.
  • First full year net revenue of US$115M achieved for Ryoncil.
  • Ryoncil is FDA-approved for children under 12 with steroid-refractory acute graft-versus-host disease.
  • Mesoblast anticipates continued revenue growth in the upcoming fiscal year.
  • The company has a strong capital position and strategic initiatives in place.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.